Xolremdi
Payments companies reported to CMS as associated with Xolremdi. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Xolremdi, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Xolremdi
These are the largest totals companies reported as associated with Xolremdi. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Serge Alexanian | Los Angeles, CA | Anatomic Pathology & Clinical Pathology | $180,000.00 |
| Mark Fleming | Boston, MA | Hematology (Pathology) | $20,250.00 |
| Niraj Patel | Durham, NC | Pediatric Allergy/Immunology | $18,406.84 |
| Sherif Badawy | Chicago, IL | Pediatric Hematology-Oncology | $14,842.82 |
| Julia Warren | Philadelphia, PA | Pediatric Hematology-Oncology | $13,088.06 |
| Kelly Walkovich | Ann Arbor, MI | Pediatric Hematology-Oncology | $10,444.00 |
| Olga Weinberg | Dallas, TX | Anatomic Pathology | $8,800.00 |
| Peter Newburger | Worcester, MA | Pediatric Hematology-Oncology | $7,154.09 |
| Peter Chang | Waltham, MA | Ophthalmology | $6,000.00 |
| Antoine Azar | Baltimore, MD | Allergy & Immunology (Internal Medicine) | $5,827.50 |
Prescribed Xolremdi?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.